523144 MEDICAPQ

MediCaps Share Price

 

 

Start SIP in MEDICAPQ

Start SIP

Performance

  • Low
  • ₹30
  • High
  • ₹33
  • 52 Week Low
  • ₹28
  • 52 Week High
  • ₹55
  • Open Price₹33
  • Previous Close₹33
  • Volume5,297
  • 50 DMA₹33.38
  • 100 DMA₹35.66
  • 200 DMA₹38.85

Investment Returns

  • Over 1 Month -1.87%
  • Over 3 Month -13.65%
  • Over 6 Month -30.07%
  • Over 1 Year -37.54%

Smart Investing Starts Here Start SIP with MediCaps for Steady Growth!

Invest Now

MediCaps Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • -6.9
  • PEG Ratio
  • 0
  • Market Cap Cr
  • 39
  • P/B Ratio
  • 0.3
  • Average True Range
  • 2.47
  • EPS
  • -
  • Dividend Yield
  • 0
  • MACD Signal
  • -0.62
  • RSI
  • 42.3
  • MFI
  • 65.46

MediCaps Financials

MediCaps Technicals

EMA & SMA

Current Price
₹31.00
-2 (-6.06%)
pointer
  • Bearish Moving Average 16
  • Bullish Moving Average 0
  • 20 Day
  • ₹31.84
  • 50 Day
  • ₹33.38
  • 100 Day
  • ₹35.66
  • 200 Day
  • ₹38.85

Resistance and Support

31.01 Pivot Speed
  • R3 35.83
  • R2 34.41
  • R1 32.43
  • S1 29.03
  • S2 27.61
  • S3 25.63

MediCaps Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2025-11-12 Quarterly Results
2025-08-05 Quarterly Results
2025-05-21 Audited Results
2025-02-12 Quarterly Results
2024-11-12 Quarterly Results

MediCaps F&O

MediCaps Shareholding Pattern

50.77%
0.01%
0.02%
44.31%
4.89%

MediCaps FAQs

MediCaps share price is ₹31 As on 17 January, 2026 | 14:24

The Market Cap of MediCaps is ₹38.7 Cr As on 17 January, 2026 | 14:24

The P/E ratio of MediCaps is -6.9 As on 17 January, 2026 | 14:24

The PB ratio of MediCaps is 0.3 As on 17 January, 2026 | 14:24

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23